查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2103320

微量殘存疾病檢測市場：全球市場預測，2026-2032年

Minimal Residual Disease Testing Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，微量殘存疾病(MRD) 檢測市場將成長至 44.7 億美元，複合年成長率為 11.55%。

主要市場統計數據
基準年 2025 20.8億美元
預計年份：2026年 23.1億美元
預測年份 2032 44.7億美元
複合年成長率 (%) 11.55%

微量殘存疾病（MRD）檢測正日益成為精準腫瘤學的關鍵要素，尤其是在急性淋巴性白血病、急性骨髓性白血病慢性淋巴性白血病白血病、多發性骨髓瘤和淋巴瘤等骨髓惡性腫瘤。透過檢測治療後殘留的少量惡性細胞，MRD檢測有助於風險分層、治療反應評估、復發監測以及治療方案的逐步減量或強化決策。多參數流式細胞技術、聚合酵素鏈鎖反應（PCR）、次世代定序和新型液態生物檢體技術的進步，提高了分析靈敏度並實現了更精細的疾病監測，推動了MRD檢測在臨床實踐中的應用。監管機構和臨床指南制定者日益認知到MRD是血液學臨床試驗的關鍵終點，這進一步提升了其在藥物研發和病患管理中的重要性。這一趨勢也受到癌症診斷基礎設施的擴展、對個人化醫療日益成長的需求、臨床試驗中微小殘留疾病（MRD）終點指標的廣泛應用，以及對標準化檢測方法、報告閾值和保險報銷途徑的需求等因素的影響。隨著癌症治療向可衡量、循證的療效指標轉變，微量殘存疾病）檢測被定位為一項高價值的診斷功能，它將檢查室創新、治療決策和長期生存計劃緊密聯繫起來。

微小殘留疾病檢測趨勢的變革性變化

隨著癌症治療從形態學反應評估轉向分子指導的監測，微小殘留疾病（MRD）檢測領域正經歷重大變革。次世代定序技術能夠高靈敏度地檢測患者特異性癌症標記物，而先進的流式細胞技術仍然是許多血液系統疾病中快速且臨床上成熟的評估工具。 MRD作為臨床試驗替代終點的應用日益廣泛，加速了檢測方法的檢驗，並促進了診斷測試開發商、臨床醫生、監管機構和保險公司之間更緊密的合作。另一個重要的轉變是從單次檢測轉向縱向監測，這使得醫生能夠追蹤疾病在整個治療過程中的動態變化。此外，液態生物檢體的研究正在拓展微創MRD評估的可能性，尤其是在骨髓穿刺負擔過重或需要重複監測的情況下。然而，該領域仍面臨許多挑戰，包括檢查室差異、靈敏度閾值不同、檢體處理要求以及臨床解讀標準化的必要性。這些變化推動了對綜合診斷平台、品質保證計劃、臨床醫生教育和循證框架的需求，這些框架將 MRD 狀態與有意義的結果（如進展風險、移植決策和治療持續時間）聯繫起來。

人工智慧對微小殘留疾病檢測的累積影響

人工智慧 (AI) 透過提升複雜診斷資料集的模式識別能力、簡化工作流程和增強臨床解讀，正在增強微量殘存疾病(MRD) 來檢測生態系統。在流式細胞技術中，AI 驅動的分析工具有助於識別更一致的細胞群、減少人工設門操作的差異，並有助於檢測罕見的異常細胞特徵。在次世代定序工作流程中，機器學習技術可以幫助抑制誤差、對突變進行分類、追蹤克隆類型，並從背景雜訊中識別訊號，這對於測量極低疾病負荷至關重要。 AI 還具有將 MRD 結果與影像學、病理學、基因組學、治療史和電子健康記錄數據整合的潛力，從而支持更個性化的複發風險模型。在臨床研究中，AI 可以幫助識別患者亞群、最佳化採樣方案，並利用 MRD 狀態改善臨床試驗的終點分析。然而，負責任地實施 AI 需要透明的檢驗、偏差監測、資料管治、網路安全措施以及臨床醫生可信賴且可解釋的輸出。因此，AI 的累積影響遠不止於自動化；它有助於將 MRD 檢測從高度專業化的實驗室測量轉變為更具擴充性、標準化和臨床實用性的決策支援功能。

關於微小殘留疾病（MRD）檢測的關鍵區域見解

在亞太地區，中國、日本、印度、韓國、澳洲以及整個東南亞地區正積極推動微量殘存疾病（MRD）檢測的普及，這得益於癌症診斷能力的提升、血液疾病治療的增加、分子檢查室的可及性提高以及政府主導的癌症基礎設施投資。北美地區在MRD檢測方面仍然非常成熟，這得益於先進的腫瘤中心、廣泛的臨床試驗活動、完善的分子病理學能力以及MRD終點在血液腫瘤研究和治療方案中的有效整合。在拉丁美洲，分子診斷的逐步普及、腫瘤專科診療的改善以及區域性檢查室品質提升的努力正在推動MRD檢測的發展，但成本效益和基礎設施不平衡仍然限制著MRD檢測的普及率。在歐洲，完善的臨床指南制定、學術血液學網路、跨境研究合作以及對治療路徑中診斷標準（特別是白血病和多發性骨髓瘤的診斷標準）協調化的日益重視，都為MRD檢測的推廣提供了助力。在中東，對三級醫院、癌症中心和基因組醫學舉措的投資正在改善人們獲得先進微小殘留疾病（MRD）檢測的機會，尤其是在那些注重精準醫療的醫療體系中。在整個非洲，MRD檢測的普及程度仍然相對有限，但隨著腫瘤學領域能力建設的加強、與參考檢測實驗室的合作以及對白血病和淋巴瘤診斷日益成長的興趣，這一進程正在取得進展。然而，檢測的可及性、培訓和檢體運輸仍然是亟待解決的核心挑戰。

關於微小殘留疾病（MRD）檢測的關鍵群體分析

在東南亞國協，由於癌症治療體系的改善以及區域醫療體系對血液疾病診斷的普及，人們對微量殘存疾病（MRD）檢測的興趣日益濃厚。然而，在先進的都市區醫院和資源匱乏的醫療機構之間，MRD檢測的實施情況存在顯著差異。在海灣合作理事會（GCC）地區，透過投資建設專科癌症中心、基因組醫學和先進的檢測基礎設施，優先發展精準腫瘤學，為在白血病、多發性骨髓瘤和淋巴瘤的治療中實施MRD檢測創造了有利環境。歐盟透過協調的臨床研究、品質標準、衛生技術評估流程以及跨境合作，為推動MRD檢測提供了最強力的框架之一，使癌症診斷與實證醫學接軌。金磚國家（BRICS）擁有大規模的患者群體、快速發展的腫瘤基礎設施、不斷提升的本地分子檢測能力以及擴大精準醫療覆蓋範圍的政策承諾，因此對MRD檢測的未來發展至關重要。然而，在保險報銷和專科醫生資源方面仍然存在差異。七國集團（G7）憑藉其先進的醫療保健體系、廣泛的轉化研究以及強力的監管支持，已為微小殘留病灶（MRD）的臨床應用做好了充分準備，這些優勢使其能夠將MRD確立為生物標記和臨床試驗終點。北約成員國與主要的腫瘤研究市場高度重合，並受益於強大的實驗室網路，但MRD的普及應用仍取決於各國醫保報銷政策、是否納入臨床實踐指南以及當地的診斷能力。

主要國家微小殘留疾病檢測趨勢

美國在微量殘存疾病（MRD）檢測的普及方面處於世界領先地位，這得益於其先進的癌症中心、完善的分子診斷基礎設施以及MRD在骨髓惡性腫瘤臨床試驗中的廣泛應用。在加拿大，MRD檢測的普及正透過公共資助的癌症計畫、學術血液學網路以及不斷擴展的精準腫瘤學工作逐步推進，儘管各州之間的可及性可能存在差異。在墨西哥，腫瘤診斷在主要大都市地區正在擴展，MRD檢測在治療特定類型的白血病和骨髓瘤的重要性日益凸顯，但保險報銷和實驗室資源的可及性仍然是重要的考慮因素。在巴西，支持MRD檢測的腫瘤科醫生和參考檢查室的基礎設施正在不斷完善，尤其是在主要的私立和學術機構，但不同地區之間仍存在可及性差異。在英國，一項全國性的癌症控制計劃、集中式檢測模式以及支持循證MRD檢測的積極臨床研究都取得了成功。在德國，高度發展的臨床實驗室醫學生態系統和強大的血液學研究基礎為臨床實踐和臨床試驗中先進的微小殘留疾病（MRD）檢測應用提供了有力支持。法國正透過癌症研究網路和精準醫療計畫加強MRD檢測的整合，而義大利和西班牙則透過專業中心和基於指南的醫療模式，持續拓展其分子血液學能力。在俄羅斯，大都會圈已具備血液學專業知識，但區域差異影響先進分子監測的普及。中國正透過專科腫瘤醫院、定序能力以及對國家精準醫療計畫的大規模投資，迅速擴大MRD檢測的覆蓋範圍。在印度，隨著癌症中心採用分子診斷技術，MRD檢測的需求不斷成長，但成本和地理限制仍然是主要限制因素。日本擁有強大的臨床研究能力、先進的診斷基礎設施，並且對血液腫瘤標準化MRD檢測方法抱持濃厚的興趣。澳洲正透過組織完善的癌症醫療網路、分子病理學專業知識以及參與國際調查，推動MRD檢測的普及。韓國憑藉其先進的醫院系統、強大的定序能力和健全的數位醫療環境，已成為先進MRD檢測流程的關鍵市場。

為行業領導者提供的實用建議

產業領導者應優先考慮臨床檢驗、檢測方法標準化和證據生成，以證明微量殘存疾病(MRD) 檢測如何改善治療決策和患者預後。 MRD 檢測解決方案的開發人員應使檢測的敏感度、特異性、檢體要求和報告格式與疾病特異性臨床指南和臨床試驗方案保持一致。實驗室應投資於品管系統、能力測試、自動化和人力資源開發，以減少變異性並提高可重複性。醫療服務提供者應將 MRD 檢測結果納入多學科腫瘤委員會討論，以便根據 MRD 陽性、陰性或隨時間的變化製定明確的治療策略。保險公司和醫療保健系統應透過基於結果的證據評估 MRD 檢測，考慮其在預防復發、移植計劃、治療最佳化和避免不必要治療方面的作用。相關人員還應透過參考實驗室模式、數位化報告工具和合作來擴大檢測的可近性，以支持服務不足的地區。對於人工智慧驅動的 MRD 工作流程，領導者應強制要求進行透明的檢驗、實際效能監測並遵守資料保護標準。最成功的策略將結合科學嚴謹性、臨床適用性、保險報銷合規性以及對腫瘤學家、病理學家、實驗室專業和患者的教育。

MRD（醫學研究診斷）分析的調查方法

分析微量殘存疾病（MRD）檢測的調查方法應結合二手資料研究、一手檢驗和結構化的專家解讀。二手資料研究應包括對同行評審的腫瘤學和血液學文獻、臨床實踐指南、監管文件、臨床試驗註冊資訊、衛生技術評估（HTA）出版物、報銷政策以及與MRD檢測相關的檢查室標準的回顧。一手研究應包括對血液科醫生、腫瘤科醫生、分子病理學家、實驗室管理人員、臨床試驗研究人員、報銷專家和醫療系統決策者的訪談，以檢驗其應用促進因素、運營挑戰和臨床應用案例。分析應按疾病領域、技術平台、檢體類型、最終用戶、醫療機構和地區對研究結果進行分類，同時避免不合理的假設。數據檢驗對於比較文獻結果、專家意見、監管趨勢和觀察到的臨床實踐趨勢至關重要。品管應強調資訊來源的可靠性、及時性、方法透明度和區域一致性。由於微小殘留病灶（MRD）檢測高度依賴臨床背景，因此解讀結果需要區分其在骨髓惡性腫瘤中的成熟應用和在固體癌中的新興應用。這種實證調查方法確保結論由檢驗的臨床、監管和營運數據支持，而非推測性的預測。

結論

微量殘存疾病（MRD）檢測正在重新定義我們衡量、監測和​​應對癌症療效的方式。這一趨勢在骨髓惡性腫瘤中尤其顯著，因為對殘留癌細胞的高靈敏度檢測能夠提供基於風險的治療指南。次世代定序、先進的流式細胞技術、基於PCR的技術、液態生物檢體檢查以及人工智慧驅動的分析正在推動這一領域的發展，所有這些技術都提高了檢測的靈敏度、擴充性和結果解讀的一致性。在腫瘤基礎設施完善、保險報銷機制健全、臨床試驗活動頻繁且檢查室品管系統良好的地區，MRD檢測的普及程度最高；而新興地區則正在透過專業中心和參考檢測網路來提升檢測能力。未來的進展取決於標準化、臨床效用證據、公平取得以及數位化工具的合理整合。對於醫療保健相關人員而言，MRD檢測為更精準的治療決策、更早的復發檢測以及根據個別患者風險量身定做的最佳化治療強度提供了途徑。專注於檢驗的檢測方法、可互通的報告、臨床醫生教育和協作證據產生的組織，將最有利於支持 MRD 檢測在精準腫瘤學中不斷擴大的作用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：微量殘存疾病檢測市場：依檢測類型分類

  • 細胞遺傳學檢測
    • 染色體微陣列
    • 螢光原位雜合反應（FISH）
  • 流式細胞技術
    • 多參數流式細胞技術
    • 單參數流式細胞技術
  • 次世代定序（NGS）
    • 標靶定序
    • 全基因測序
  • 聚合酵素鏈鎖反應（PCR）
    • 數位PCR
    • 定量PCR

第8章：微量殘存疾病檢測市場：依樣本類型分類

  • 血
    • 電漿
    • 血清
  • 骨髓
  • 腦脊髓液（CSF）
  • 組織切片檢查
  • 尿

第9章：微量殘存疾病檢測市場：依應用領域分類

  • 白血病
    • 急性淋巴性白血病（ALL）
    • 急性骨髓性白血病（AML）
    • 慢性淋巴性白血病（CLL）
  • 淋巴瘤
    • 何傑金氏淋巴瘤
    • 非何傑金氏淋巴瘤
  • 多發性骨髓瘤
  • 固態腫瘤
    • 乳癌
    • 結腸癌

第10章：微量殘存疾病檢測市場：以終端用戶產業分類

  • 學術研究機構
  • 生物製藥公司
  • 診斷檢查室
  • 醫院

第11章：微量殘存疾病檢測市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章：微量殘存疾病檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：微量殘存疾病檢測市場：依國家分類

  • 美國
  • 德國
  • 中國
  • 英國
  • 印度
  • 日本
  • 俄羅斯
  • 巴西
  • 加拿大
  • 義大利
  • 墨西哥
  • 法國
  • 西班牙
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Adaptive Biotechnologies Corporation
  • Agilus Diagnostics Ltd.
  • Amgen Inc.
  • ARUP Laboratories
  • AstraZeneca PLC
  • Asuragen Inc. by Bio-Techne Corporation
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Genetron Holdings Limited
  • GRAIL, LLC by Illumina, Inc.
  • Guardant Health, Inc.
  • Integrated DNA Technologies, Inc.
  • Invivoscribe, Inc.
  • Kite Pharma, Inc. by Gilead Sciences, Inc.
  • Laboratory Corporation of America Holdings
  • MedGenome Inc
  • Mission Bio, Inc.
  • Myriad Genetics, Inc.
  • Natera Inc.
  • NeoGenomics Laboratories, Inc.
  • OPKO Health, Inc.
  • Quest Diagnostics incorporated
  • Sysmex Corporation
  • Veracyte, Inc.
Product Code: MRR-961BA04A2E6C

The Minimal Residual Disease Testing Market is projected to grow by USD 4.47 billion at a CAGR of 11.55% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.08 billion
Estimated Year [2026] USD 2.31 billion
Forecast Year [2032] USD 4.47 billion
CAGR (%) 11.55%

Minimal residual disease testing is becoming a critical component of precision oncology, especially in hematologic malignancies such as acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, and lymphoma. By detecting very low levels of malignant cells that remain after treatment, MRD testing supports risk stratification, therapy response assessment, relapse monitoring, and treatment de-escalation or intensification decisions. Clinical adoption is being shaped by advances in multiparameter flow cytometry, polymerase chain reaction, next-generation sequencing, and emerging liquid biopsy approaches that improve analytical sensitivity and enable deeper disease surveillance. Regulatory agencies and clinical guideline bodies increasingly recognize MRD as an important endpoint in hematology trials, reinforcing its relevance in drug development and patient management. The landscape is also influenced by expanding oncology diagnostics infrastructure, growing demand for personalized medicine, increasing clinical trial use of MRD endpoints, and the need for standardized assays, reporting thresholds, and reimbursement pathways. As cancer care shifts toward measurable, evidence-based outcomes, minimal residual disease testing is positioned as a high-value diagnostic capability connecting laboratory innovation, therapeutic decision-making, and long-term survivorship planning.

Transformative Shifts in the MRD Testing Landscape

The minimal residual disease testing landscape is undergoing a significant transformation as oncology care moves from morphology-based response assessment toward molecularly guided monitoring. Next-generation sequencing is enabling highly sensitive detection of patient-specific cancer markers, while advanced flow cytometry continues to provide rapid, clinically established assessment in many hematology settings. The growing use of MRD as a surrogate endpoint in clinical trials is accelerating assay validation and encouraging greater alignment between diagnostic developers, clinicians, regulators, and payers. Another important shift is the movement from single time-point testing to longitudinal monitoring, allowing physicians to track disease dynamics over the treatment journey. Liquid biopsy research is also expanding the potential for less invasive MRD assessment, particularly where bone marrow sampling is burdensome or repeated monitoring is required. At the same time, the sector faces persistent challenges, including inter-laboratory variability, differences in sensitivity thresholds, sample handling requirements, and the need for harmonized clinical interpretation. These shifts are creating demand for integrated diagnostic platforms, quality assurance programs, clinician education, and evidence frameworks that connect MRD status with meaningful outcomes such as progression risk, transplant decisions, and therapy duration.

Cumulative Impact of Artificial Intelligence on MRD Testing

Artificial intelligence is strengthening the minimal residual disease testing ecosystem by improving pattern recognition, workflow efficiency, and clinical interpretation across complex diagnostic datasets. In flow cytometry, AI-enabled analytical tools can support more consistent cell population identification, reduce manual gating variability, and help detect rare abnormal cell signatures. In next-generation sequencing workflows, machine learning methods can assist with error suppression, variant classification, clonotype tracking, and signal differentiation from background noise, which is essential when measuring extremely low disease burden. AI also has potential to integrate MRD results with imaging, pathology, genomics, treatment history, and electronic health record data to support more personalized relapse risk models. In clinical research, AI can help identify patient subgroups, optimize sampling schedules, and improve endpoint analysis in trials using MRD status. However, responsible deployment requires transparent validation, bias monitoring, data governance, cybersecurity protections, and explainable outputs that clinicians can trust. The cumulative impact of AI is therefore not limited to automation; it is helping transform MRD testing from a highly specialized laboratory measurement into a more scalable, standardized, and clinically actionable decision-support capability.

Key Regional Insights for MRD Testing

In Asia-Pacific, adoption of minimal residual disease testing is supported by expanding cancer diagnostics capacity, rising hematology treatment volumes, growing access to molecular laboratories, and government-led investments in oncology infrastructure across China, Japan, India, South Korea, Australia, and Southeast Asia. North America remains a highly mature environment for MRD testing due to advanced oncology centers, broad clinical trial activity, established molecular pathology capabilities, and strong integration of MRD endpoints in hematologic cancer research and treatment protocols. Latin America is advancing through gradual expansion of molecular diagnostics, improved access to specialized oncology care, and regional efforts to strengthen laboratory quality, although affordability and uneven infrastructure continue to shape adoption. Europe benefits from robust clinical guideline development, academic hematology networks, cross-border research collaboration, and increasing emphasis on harmonized diagnostic standards, particularly in leukemia and multiple myeloma care pathways. In the Middle East, investment in tertiary hospitals, cancer centers, and genomic medicine initiatives is improving access to advanced MRD testing, especially in health systems focused on precision medicine. Across Africa, MRD testing adoption remains comparatively limited but is developing through oncology capacity-building, reference laboratory partnerships, and growing attention to leukemia and lymphoma diagnostics, with access, training, and sample logistics remaining central challenges.

Key Group Insights for MRD Testing

ASEAN countries are seeing growing interest in minimal residual disease testing as cancer care capacity improves and regional health systems expand access to hematology diagnostics, although adoption varies widely between advanced urban hospitals and resource-constrained settings. The GCC region is prioritizing precision oncology through investments in specialized cancer centers, genomic medicine, and advanced laboratory infrastructure, creating favorable conditions for MRD testing in leukemia, myeloma, and lymphoma management. The European Union provides one of the strongest frameworks for MRD advancement through coordinated clinical research, quality standards, health technology assessment processes, and cross-country efforts to align cancer diagnostics with evidence-based care. BRICS economies are important to the future of MRD testing because they combine large patient populations with rapidly developing oncology infrastructure, increasing local molecular testing capacity, and policy interest in expanding access to precision medicine, while still facing disparities in reimbursement and specialist availability. G7 countries have high clinical readiness for MRD integration due to advanced healthcare systems, extensive translational research, and strong regulatory engagement with MRD as a biomarker and clinical trial endpoint. NATO member countries overlap substantially with major oncology research markets and benefit from strong laboratory networks, but adoption patterns remain tied to national reimbursement decisions, guideline inclusion, and local diagnostic capacity.

Key Country Insights for MRD Testing

The United States is a leading adopter of minimal residual disease testing, supported by advanced cancer centers, strong molecular diagnostics infrastructure, and extensive clinical trial use of MRD in hematologic malignancies. Canada is advancing MRD implementation through publicly funded cancer programs, academic hematology networks, and growing precision oncology initiatives, though access may differ by province. Mexico is expanding oncology diagnostics in major urban centers, with MRD testing increasingly relevant for specialized leukemia and myeloma care, while reimbursement and laboratory access remain important considerations. Brazil has a growing base of oncology specialists and reference laboratories supporting MRD use, particularly in major private and academic settings, with access gaps across regions. The United Kingdom benefits from national cancer strategies, centralized testing models, and strong clinical research activity that support evidence-based MRD adoption. Germany has a well-developed laboratory medicine ecosystem and robust hematology research base, supporting advanced MRD applications in clinical practice and trials. France is strengthening MRD integration through cancer research networks and precision medicine programs, while Italy and Spain continue to expand molecular hematology capabilities through specialized centers and guideline-driven care. Russia has established hematology expertise in large urban centers, but regional variability affects access to advanced molecular monitoring. China is rapidly expanding MRD testing through major investments in oncology hospitals, sequencing capacity, and domestic precision medicine programs. India is experiencing growing demand for MRD testing as cancer centers adopt molecular diagnostics, though affordability and geographic access remain key constraints. Japan has strong clinical research capabilities, advanced diagnostics infrastructure, and high interest in standardized MRD approaches for hematologic cancers. Australia supports MRD adoption through well-organized cancer care networks, molecular pathology expertise, and participation in international research. South Korea's advanced hospital systems, high sequencing capability, and strong digital health environment position it as an important market for sophisticated MRD testing workflows.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinical validation, assay standardization, and evidence generation that demonstrate how minimal residual disease testing improves treatment decisions and patient outcomes. Developers of MRD testing solutions should align assay sensitivity, specificity, sample requirements, and reporting formats with disease-specific clinical guidelines and trial protocols. Laboratories should invest in quality management systems, proficiency testing, automation, and workforce training to reduce variability and improve reproducibility. Healthcare providers should integrate MRD results into multidisciplinary tumor board discussions and establish clear pathways for action based on MRD positivity, negativity, or conversion over time. Payers and health systems should evaluate MRD testing through outcomes-based evidence, considering its role in relapse prevention, transplant planning, therapy optimization, and avoidance of unnecessary treatment exposure. Stakeholders should also expand access through reference laboratory models, digital reporting tools, and collaborations that support underserved regions. For AI-enabled MRD workflows, leaders should require transparent validation, real-world performance monitoring, and compliance with data protection standards. The most successful strategies will combine scientific rigor, clinical usability, reimbursement readiness, and education for oncologists, pathologists, laboratory professionals, and patients.

Research Methodology for MRD Testing Analysis

The research methodology for analyzing minimal residual disease testing should combine secondary research, primary validation, and structured expert interpretation. Secondary research includes review of peer-reviewed oncology and hematology literature, clinical practice guidelines, regulatory documents, clinical trial registries, health technology assessment publications, reimbursement policies, and laboratory standards related to MRD testing. Primary research should include interviews with hematologists, oncologists, molecular pathologists, laboratory directors, clinical trial investigators, reimbursement specialists, and health system decision-makers to validate adoption drivers, operational challenges, and clinical use cases. The analysis should segment insights by disease area, technology platform, sample type, end user, care setting, and geography while avoiding unsupported assumptions. Data triangulation is essential to compare literature findings, expert perspectives, regulatory developments, and observed clinical practice trends. Quality control should emphasize source credibility, recency, methodological transparency, and consistency across regions. Because MRD testing is highly dependent on clinical context, interpretation should distinguish between established applications in hematologic malignancies and emerging applications in solid tumors. This evidence-based methodology ensures that conclusions are grounded in validated clinical, regulatory, and operational intelligence rather than speculative projections.

Conclusion

Minimal residual disease testing is redefining how cancer response is measured, monitored, and acted upon, particularly in hematologic malignancies where highly sensitive detection of residual cancer cells can guide risk-adapted care. The field is being shaped by next-generation sequencing, advanced flow cytometry, PCR-based methods, liquid biopsy research, and AI-enabled analytics that improve sensitivity, scalability, and interpretive consistency. Regional adoption is strongest where oncology infrastructure, reimbursement pathways, clinical trial activity, and laboratory quality systems are well developed, while emerging regions are building capacity through specialized centers and reference testing networks. The next phase of progress will depend on standardization, clinical utility evidence, equitable access, and responsible integration of digital tools. For healthcare stakeholders, MRD testing offers a pathway to more precise treatment decisions, earlier relapse detection, and better alignment of therapy intensity with individual patient risk. Organizations that focus on validated assays, interoperable reporting, clinician education, and collaborative evidence generation will be best positioned to support the expanding role of MRD testing in precision oncology.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Minimal Residual Disease Testing Market, by Test Type

  • 7.1. Introduction
  • 7.2. Cytogenetics
    • 7.2.1. Chromosomal microarray
    • 7.2.2. Fluorescence in situ hybridization (FISH)
  • 7.3. Flow Cytometry
    • 7.3.1. Multi-parameter flow cytometry
    • 7.3.2. Single-parameter flow cytometry
  • 7.4. Next-Generation Sequencing (NGS)
    • 7.4.1. Targeted sequencing
    • 7.4.2. Whole genome sequencing
  • 7.5. Polymerase Chain Reaction (PCR)
    • 7.5.1. Digital PCR
    • 7.5.2. Quantitative PCR

8. Minimal Residual Disease Testing Market, by Sample Type

  • 8.1. Introduction
  • 8.2. Blood
    • 8.2.1. Plasma
    • 8.2.2. Serum
  • 8.3. Bone Marrow
  • 8.4. Cerebrospinal Fluid (CSF)
  • 8.5. Tissue Biopsy
  • 8.6. Urine

9. Minimal Residual Disease Testing Market, by Application Areas

  • 9.1. Introduction
  • 9.2. Leukemia
    • 9.2.1. Acute Lymphoblastic Leukemia (ALL)
    • 9.2.2. Acute Myeloid Leukemia (AML)
    • 9.2.3. Chronic Lymphocytic Leukemia (CLL)
  • 9.3. Lymphoma
    • 9.3.1. Hodgkin's lymphoma
    • 9.3.2. Non-Hodgkin's lymphoma
  • 9.4. Multiple Myeloma
  • 9.5. Solid Tumors
    • 9.5.1. Breast cancer
    • 9.5.2. Colorectal cancer

10. Minimal Residual Disease Testing Market, by End-User Vertical

  • 10.1. Introduction
  • 10.2. Academic & Research Institutes
  • 10.3. Biopharmaceutical Companies
  • 10.4. Diagnostic Laboratories
  • 10.5. Hospitals

11. Minimal Residual Disease Testing Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Minimal Residual Disease Testing Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Minimal Residual Disease Testing Market, by Country

  • 13.1. United States
  • 13.2. Germany
  • 13.3. China
  • 13.4. United Kingdom
  • 13.5. India
  • 13.6. Japan
  • 13.7. Russia
  • 13.8. Brazil
  • 13.9. Canada
  • 13.10. Italy
  • 13.11. Mexico
  • 13.12. France
  • 13.13. Spain
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. FPNV Positioning Matrix, 2025
  • 14.3. Market Concentration Analysis, 2025
    • 14.3.1. Concentration Ratio (CR)
    • 14.3.2. Herfindahl Hirschman Index (HHI)
  • 14.4. Recent Developments & Impact Analysis, 2025
  • 14.5. Product Portfolio Analysis, 2025
  • 14.6. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Adaptive Biotechnologies Corporation
  • 15.2. Agilus Diagnostics Ltd.
  • 15.3. Amgen Inc.
  • 15.4. ARUP Laboratories
  • 15.5. AstraZeneca PLC
  • 15.6. Asuragen Inc. by Bio-Techne Corporation
  • 15.7. Bio-Rad Laboratories, Inc.
  • 15.8. Bristol-Myers Squibb Company
  • 15.9. Exact Sciences Corporation
  • 15.10. F. Hoffmann-La Roche Ltd.
  • 15.11. Genetron Holdings Limited
  • 15.12. GRAIL, LLC by Illumina, Inc.
  • 15.13. Guardant Health, Inc.
  • 15.14. Integrated DNA Technologies, Inc.
  • 15.15. Invivoscribe, Inc.
  • 15.16. Kite Pharma, Inc. by Gilead Sciences, Inc.
  • 15.17. Laboratory Corporation of America Holdings
  • 15.18. MedGenome Inc
  • 15.19. Mission Bio, Inc.
  • 15.20. Myriad Genetics, Inc.
  • 15.21. Natera Inc.
  • 15.22. NeoGenomics Laboratories, Inc.
  • 15.23. OPKO Health, Inc.
  • 15.24. Quest Diagnostics incorporated
  • 15.25. Sysmex Corporation
  • 15.26. Veracyte, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 21. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CYTOGENETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CYTOGENETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CYTOGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHROMOSOMAL MICROARRAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHROMOSOMAL MICROARRAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHROMOSOMAL MICROARRAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MULTI-PARAMETER FLOW CYTOMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MULTI-PARAMETER FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MULTI-PARAMETER FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SINGLE-PARAMETER FLOW CYTOMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SINGLE-PARAMETER FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SINGLE-PARAMETER FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEXT-GENERATION SEQUENCING (NGS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT-GENERATION SEQUENCING (NGS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEXT-GENERATION SEQUENCING (NGS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DIGITAL PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIGITAL PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIGITAL PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL QUANTITATIVE PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL QUANTITATIVE PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL QUANTITATIVE PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PLASMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PLASMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PLASMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SERUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SERUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SERUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BONE MARROW MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BONE MARROW MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BONE MARROW MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CEREBROSPINAL FLUID (CSF) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CEREBROSPINAL FLUID (CSF) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CEREBROSPINAL FLUID (CSF) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TISSUE BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TISSUE BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TISSUE BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LEUKEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LEUKEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LEUKEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LYMPHOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LYMPHOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HODGKIN'S LYMPHOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HODGKIN'S LYMPHOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HODGKIN'S LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NON-HODGKIN'S LYMPHOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NON-HODGKIN'S LYMPHOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NON-HODGKIN'S LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 202. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 205. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 206. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 207. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 208. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 210. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 211. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 212. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 213. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 214. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 233. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 234. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 241. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 242. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 244. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 245. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 246. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 247. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 249. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 250. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 251. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 252. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 253. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 254. NATO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. NATO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. NATO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 257. NATO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 258. NATO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 259. NATO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 260. NATO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. NATO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 262. NATO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 263. NATO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 264. NATO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 265. NATO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 266. NATO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 281. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 282. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 284. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 285. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 286. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 287. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 289. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 290. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 291. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 292. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 293. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 299. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 300. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 312. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 313. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 320. INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 321. INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 323. INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 324. INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-203